Objective:

To discuss factors influencing the success of novel spectacle lenses for myopia control.

Key Findings:

• Faster myopia progression (> -0.50D/6m) correlates with greater benefits from optical interventions, particularly in younger children (ages 6 to 8).
• Optimal results require 12 to 14 hours of daily lens wear, which may not be achievable for many children.
• Some patients may experience mild side effects such as ghosting or glare, affecting compliance.
• Proper fitting of frames is critical for the effectiveness of novel spectacle lenses.

Interpretation:

Novel spectacle lenses represent a promising, non-invasive option for myopia control, with potential for significant impact on progression rates when used correctly.

Limitations:

• Lack of FDA approval for novel lenses in the U.S. limits their availability and use.
• Need for large-scale studies to confirm findings and assess long-term safety.
• Variability in real-world usage compared to clinical trials may reduce overall efficacy.

Conclusion:

Understanding the factors influencing treatment success will prepare U.S. optometrists to effectively assist patients once these lenses are available, emphasizing the need for ongoing research.